These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2451409)

  • 1. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
    Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
    Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
    Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
    Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study].
    Koyanagi T; Togashi M; Maru A; Orikasa S; Soma F; Shimazaki J; Yasuda K; Aso Y; Honma Y; Miyake K
    Hinyokika Kiyo; 1990 Oct; 36(10):1233-52. PubMed ID: 1979900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
    Kumamoto Y; Tsukamoto T; Takagi Y; Furuya S; Yokoyama E; Takatsuka K; Tamiya T; Miyamoto S; Aoyama T; Honma A
    Hinyokika Kiyo; 1987 Nov; 33(11):1921-41. PubMed ID: 2451412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia].
    Fujita T; Ohshima S; Asano H; Ono Y; Kinukawa T; Kato N; Hirabayashi S
    Hinyokika Kiyo; 1992 May; 38(5):613-21. PubMed ID: 1376962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction].
    Takita T; Kondo A; Mitsuya H; Otani T
    Hinyokika Kiyo; 1987 Sep; 33(9):1375-84. PubMed ID: 2449057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.
    de Reijke TM; Klarskov P
    BJU Int; 2004 Apr; 93(6):757-62. PubMed ID: 15049986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study].
    Jardin A
    Ann Urol (Paris); 1988; 22(5):333-40. PubMed ID: 2462402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of moxisylyte hydrochloride in the symptomatic treatment of benign prostatic hyperplasia].
    Izumi H; Kudo S; Fuino A; Yokoyama E; Ishibashi A
    Hinyokika Kiyo; 1989 Mar; 35(3):541-9. PubMed ID: 2472054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of symptomatic benign prostatic hypertrophy].
    Park YC; Nishioka T; Arai Y; Tomoyoshi T; Kurita T; Hayashida H; Nagai N; Inoue H; Kataoka K; Kitagawa Y
    Hinyokika Kiyo; 1992 Jul; 38(7):857-68. PubMed ID: 1381869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A double blind clinical trial of the alpha-adrenergic blocker, Ea-0643 tablet, in the treatment of neurogenic bladder].
    Murayama K; Katsumi T; Nakamura T; Tazika E; Sakai A; Haginaka T
    Hinyokika Kiyo; 1985 Oct; 31(10):1845-53. PubMed ID: 2868640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Usefulness and safety of bunazosin hydrochloride in neurogenic bladder after prolonged administration].
    Hiraga S; Satoh T; Kakehi R; Kojima S; Yokokawa M; Gotoh S; Kaneoya F; Mizuo T; Tanizawa A; Hosoda K
    Hinyokika Kiyo; 1992 Feb; 38(2):255-63. PubMed ID: 1348604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study.
    Yokoyama T; Kumon H; Nasu Y; Takamoto H; Watanabe T
    Int J Urol; 2006 Jul; 13(7):932-8. PubMed ID: 16882058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker].
    Katsumi T; Murayama K
    Hinyokika Kiyo; 1992 Sep; 38(9):1089-92. PubMed ID: 1384297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.